The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway

被引：11

作者：

Li, Luxin ^{[1
]}

Lian, Xu ^{[2
]}

Wang, Zhilong ^{[3
]}

Zheng, Junya ^{[1
]}

Liu, Jieting ^{[1
]}

Chu, Yanhui ^{[1
]}

Teng, Yanjie ^{[1
]}

Zhang, Zhen ^{[1
,3
]}

机构：

[1] Mudanjiang Med Univ, Heilongjiang Key Lab Antifibrosis Biotherapy, Hongqi Hosp, Mudanjiang, Peoples R China

[2] Mudanjiang Med Univ, Dept Endocrinol, Hongqi Hosp, Mudanjiang, Peoples R China

[3] Mudanjiang Med Univ, Sch Clin Med Coll 1, 3 Tongxiang Rd, Mudanjiang 157011, Heilongjiang, Peoples R China

来源：

PHARMAZIE | 2019年 / 74卷 / 04期

关键词：

GROWTH-FACTOR; IN-VIVO; MELLITUS; FIBROSIS; SAXAGLIPTIN; COMBINATION; EXPRESSION; CELLS;

D O I：

10.1681/ph.2019.8918

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Diabetic nephropathy (DN) is a common cause of end-stage kidney disease (ESKD) all over the world. Sitagliptin, an inhibitor of DPP-IV plays a beneficial role in type 2 diabetic nephropathy. The purpose of this study was to explore the effect and mechanism of sitagliptin on renal injury in type 1 diabetic mice. Streptozotocin (STZ) induced type 1 diabetic mice were treated with oral administration of sitagliptin (15 mg/kg/day) for 4 weeks. The results showed that sitagliptin treatment did not change the levels of blood glucose in STZ induced type 1 diabetic mice. Sitagliptin attenuates diabetic nephropathy by significantly inhibiting 24 h proteinuria, renal injury and fibrosis. Sitagliptin can inhibit the expression level of TGF-beta 1 and the other related fibrosis factors in renal tissue of type 1 diabetic mice while delaying the progression of type 1 diabetic nephropathy. These results indicated that sitagliptin treatment is potentially a new strategy for treating type 1 diabetic nephropathy.

引用

页码：239 / 242

页数：4

共 25 条

[1] Renal histologic changes and the outcome in patients with diabetic nephropathy [J].

An, Yu ;

Xu, Feng ;

Le, Weibo ;

Ge, Yongchun ;

Zhou, Minlin ;

Chen, Hao ;

Zeng, Caihong ;

Zhang, Haitao ;

Liu, Zhihong .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (02) :257-266

[2]

[Anonymous], 2011, GUIDE CARE USE LAB A

[3] DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control [J].

Bae, Eun Ju .

ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (08) :1114-1128

[4] Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility [J].

Budi, Erine H. ;

Duan, Dana ;

Derynck, Rik .

TRENDS IN CELL BIOLOGY, 2017, 27 (09) :658-672

[5] Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond [J].

Cho, Young Min ;

Fujita, Yukihiro ;

Kieffer, Timothy J. .

ANNUAL REVIEW OF PHYSIOLOGY, VOL 76, 2014, 76 :535-559

[6] Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic -cell function in hypertensive diabetic patients treated with angiotensin receptor blockers [J].

Fukui, Kensuke ;

Kawahito, Hiroyuki ;

Wakana, Noriyuki ;

Kikai, Masakazu ;

Terada, Kensuke ;

Yamamoto, Keita ;

Irie, Daisuke ;

Kato, Taku ;

Miyagawa, Sonoko ;

Yamada, Hiroyuki .

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2015, 16 (04) :1001-1009

[7] PDX1 transfection induces human adipose derived stem cells differentiation into islet-like cells: what is the benefit for diabetic rats? [J].

Gao, Jian ;

Yuan, Yue ;

Hu, Bo ;

Chen, Yuqing .

PHARMAZIE, 2018, 73 (04) :213-217

[8] Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study [J].

Iwai, Toshiki ;

Miyazaki, Mariko ;

Yamada, Gen ;

Nakayama, Masaaki ;

Yamamoto, Tae ;

Satoh, Michihiro ;

Sato, Hiroshi ;

Ito, Sadayoshi .

CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (02) :328-336

[9]

Johnson FL, 2017, J AM HEART ASSOC, V6, P7

[10] Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].

Livak, KJ ;

Schmittgen, TD .

METHODS, 2001, 25 (04) :402-408

← 1 2 3 →